CAR-T cell therapy: a potential new strategy against prostate cancer
G Schepisi, MC Cursano, C Casadei, C Menna… - … for immunotherapy of …, 2019 - Springer
Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the
present immunotherapy era, several immunotherapeutic agents have been evaluated in …
present immunotherapy era, several immunotherapeutic agents have been evaluated in …
Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery
H Wu, H Shi, H Zhang, X Wang, Y Yang, C Yu, C Hao… - Biomaterials, 2014 - Elsevier
Multiwalled carbon nanotubes (MWCNTs) are cut short and grafted with polyethylenimine
(PEI) for further covalent conjugation to fluorescein isothiocyanate (FITC) and prostate stem …
(PEI) for further covalent conjugation to fluorescein isothiocyanate (FITC) and prostate stem …
Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy
Y Ling, K Wei, Y Luo, X Gao, S Zhong - Biomaterials, 2011 - Elsevier
Theragnostics polymer nanoparticles (NPs) loaded simultaneously with anticancer drug
docetaxel (Dtxl) and superparamagnetic iron oxide (SPIO) nanocrystals were developed for …
docetaxel (Dtxl) and superparamagnetic iron oxide (SPIO) nanocrystals were developed for …
Advances in immuno–positron emission tomography: antibodies for molecular imaging in oncology
SM Knowles, AM Wu - Journal of Clinical Oncology, 2012 - ascopubs.org
Identification of cancer cell–surface biomarkers and advances in antibody engineering have
led to a sharp increase in the development of therapeutic antibodies. These same advances …
led to a sharp increase in the development of therapeutic antibodies. These same advances …
Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases …
HJK Ananias, MC van den Heuvel, W Helfrich… - The …, 2009 - Wiley Online Library
OBJECTIVE Cell membrane antigens like the gastrin‐releasing peptide receptor (GRPR),
the prostate stem cell antigen (PSCA), and the prostate‐specific membrane antigen (PSMA) …
the prostate stem cell antigen (PSCA), and the prostate‐specific membrane antigen (PSMA) …
Survey of the year 2007 commercial optical biosensor literature
RL Rich, DG Myszka - Journal of Molecular Recognition: An …, 2008 - Wiley Online Library
In 2007, 1179 papers were published that involved the application of optical biosensors.
Reported developments in instrument hardware, assay design, and immobilization …
Reported developments in instrument hardware, assay design, and immobilization …
Prostate stem cell antigen: a Jekyll and Hyde molecule?
N Saeki, J Gu, T Yoshida, X Wu - Clinical Cancer Research, 2010 - AACR
Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell
surface protein. Although PSCA is thought to be involved in intracellular signaling, much …
surface protein. Although PSCA is thought to be involved in intracellular signaling, much …
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells
X Wei, Y Lai, J Li, L Qin, Y Xu, R Zhao, B Li, S Lin… - …, 2017 - Taylor & Francis
In recent years, immunotherapies, such as those involving chimeric antigen receptor (CAR)
T cells, have become increasingly promising approaches to non-small-cell lung cancer …
T cells, have become increasingly promising approaches to non-small-cell lung cancer …
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?
MP Deonarain, CA Kousparou, AA Epenetos - MAbs, 2009 - Taylor & Francis
Antibody targeting of cancer is showing clinical and commercial success after much intense
research and development over the last 30 years. They still have the potential to delivery …
research and development over the last 30 years. They still have the potential to delivery …